ClinicaliQ Trial Snapshot
- Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B — Recruiting • Phase III • NCT07080905.
- CSL222 Trial Summary.
- CSL222 gene therapy tested in teenage boys with moderate-to-severe hemophilia B for safety, tolerability, and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B. Conditions: Hemophilia B Interventions: CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) Lead Sponsor: CSL Behring Planned Enrollment: 20 participants